



(51) International Patent Classification:

C12N 15/67 (2006.01) C12N 5/071 (2010.01)
C07K 14/47 (2006.01)

(21) International Application Number:

PCT/US2019/067455

(22) International Filing Date:

19 December 2019 (19.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/784,051 21 December 2018 (21.12.2018) US

(71) Applicant (for all designated States except BE, CN, CY, FR, GR, IE, IN, IT, LT, LV, MC, MT, NL, SI): **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(71) Applicant (for AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

only): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(72) Inventors: **ARENA, Tia Alexandra**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **WONG, Athena W.**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US).


(74) Agent: **LEKUTIS, Christine**; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: METHODS OF PRODUCING POLYPEPTIDES USING A CELL LINE RESISTANT TO APOPTOSIS

FIG. 1A



(57) Abstract: Provided herein are cell lines (e.g., HEK293 cell lines) that comprise a loss-of-function mutation in each of the human *Bax* and *Bak* genes, as well as cell cultures comprising the cell lines. The cell lines and/or cell cultures may find use, e.g., in methods for producing a recombinant polypeptide (such as an antibody or antigen-binding fragment thereof) or a viral vector.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*